Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.-论文-万方医学网

第一作者： Aleksandar,Sekulic

第一单位： Mayo Clinic, Scottsdale, Arizona. Electronic address: sekulic.aleksandar@mayo.edu.

作者： Aleksandar,Sekulic ^[1] ; Michael R,Migden ^[2] ; Karl,Lewis ^[3] ; John D,Hainsworth ^[4] ; James A,Solomon ^[5] ; Simon,Yoo ^[6] ; Sarah T,Arron ^[7] ; Philip A,Friedlander ^[8] ; Ellen,Marmur ^[9] ; Charles M,Rudin ^[10] ; Anne Lynn S,Chang ^[11] ; Luc,Dirix ^[12] ; Jeannie,Hou ^[13] ; Huibin,Yue ^[13] ; Axel,Hauschild ^[14] ; ERIVANCE BCC investigators

作者单位： Mayo Clinic, Scottsdale, Arizona. Electronic address: sekulic.aleksandar@mayo.edu. ^[1] University of Texas MD Anderson Cancer Center, Houston, Texas. ^[2] University of Colorado Cancer Center, Denver, Colorado. ^[3] Sarah Cannon Research Institute, Nashville, Tennessee. ^[4] Ameriderm Research, Ormond Beach, Florida; University of Central Florida, Orlando, Florida; University of Illinois, Urbana, Illinois. ^[5] Northwestern University, Evanston, Illinois. ^[6] University of California, San Francisco, San Francisco, California. ^[7] Dana-Farber Cancer Institute, Boston, Massachusetts; Mount Sinai Medical Center, New York, New York. ^[8] Mount Sinai Medical Center, New York, New York. ^[9] Johns Hopkins University, Baltimore, Maryland. ^[10] Stanford University School of Medicine, Palo Alto, California. ^[11] Sint-Augustinus Hospital, Antwerp, Belgium. ^[12] Genentech Inc, South San Francisco, California. ^[13] Universitätsklinikum Schleswig-Holstein, Kiel, Germany. ^[14]

医学主题词投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);酰苯胺类(Anilides);癌, 基底细胞(Carcinoma, Basal Cell);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);中年人(Middle Aged);肿瘤侵润(Neoplasm Invasiveness);肿瘤分期(Neoplasm Staging);吡啶类(Pyridines);危险性评估(Risk Assessment);皮肤肿瘤(Skin Neoplasms);存活率分析(Survival Analysis);时间因素(Time Factors);治疗结果(Treatment Outcome)

DOI 10.1016/j.jaad.2015.03.021

PMID 25981002

发布时间 2022-03-31

检索历史清除

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

Journal of the American Academy of Dermatology

相似文献

同项目论文

Journal of the American Academy of Dermatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

Journal of the American Academy of Dermatology

相似文献

同项目论文

Journal of the American Academy of Dermatology

相关期刊

检索历史清除